Asthma caused by durvalumab after chemoradiotherapy in two patients with non‐small cell lung cancer
Abstract Durvalumab, an anti‐programmed cell death‐ligand 1 (PD‐L1) antibody, is currently used in the maintenance therapy for patients with stage III non‐small cell lung cancer after platinum‐based chemoradiotherapy. A 69‐year‐old male with lung adenocarcinoma, clinical stage IIIA, was treated with...
Main Authors: | Takehiro Uemura, Kensuke Fukumitsu, Ken Maeno, Satoshi Fukuda, Tomohiro Onuki, Yoshihiro Kanemitsu, Tetsuya Oguri, Akio Niimi, Toyoaki Hida |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-09-01
|
Series: | Respirology Case Reports |
Subjects: | |
Online Access: | https://doi.org/10.1002/rcr2.835 |
Similar Items
-
Durvalumab induced sarcoid‐like pulmonary lymphadenopathy
by: Emma Sanderson, et al.
Published: (2020-04-01) -
Retinal Vasculitis Secondary to Durvalumab
by: Antonio R. Andrade, et al.
Published: (2020-05-01) -
Long‐term response with durvalumab after chemoradiotherapy for pulmonary pleomorphic carcinoma: A case report
by: Takafumi Yorozuya, et al.
Published: (2020-04-01) -
Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma
by: Faiena I, et al.
Published: (2018-01-01) -
Anti‐TIF1γ antibody‐positive dermatomyositis associated with durvalumab administration in a patient with lung and oesophageal cancers
by: Ryosuke Imai, et al.
Published: (2021-04-01)